Plasma cell neoplasms represent a spectrum of diseases progressing from monoclonal gammopathy of undetermined significance (MGUS) to asymptomatic multiple myeloma (MM) to symptomatic MM. Significant advances in the management of MM continue to help increase survival and quality of life for patients. Prior to initiating treatment, diagnosis confirmation and risk stratification are crucial, particularly with transplant eligibility as that can direct initial treatment choices. Major drug classes for treating MM have included alkylating agents, anthracyclines, and corticosteroids for years, but immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) have changed the landscape improving responses and outcomes for patients.
|Original language||English (US)|
|Title of host publication||Plasma Cell Neoplasms|
|Subtitle of host publication||A Morphologic, Cytogenetic and Immunophenotypic Approach|
|Publisher||Springer International Publishing|
|Number of pages||19|
|State||Published - Jan 1 2015|